Theodore Schroeder Biography and Net Worth

CEO of Nabriva Therapeutics

Ted Schroeder joined Nabriva Therapeutics plc in July 2018. During the last 30 years, he has been focused on drug development and commercialization in both large and small pharmaceutical companies. Most recently, Ted served as president, chief executive officer and director of Zavante Therapeutics until its acquisition by Nabriva Therapeutics in 2018. Ted co-founded Cadence Pharmaceuticals in 2004 and previously held leadership roles at Elan Pharmaceuticals, Dura Pharmaceuticals and earlier in his career, Bristol-Myers Squibb. He currently serves on the board of Cidara Therapeutics (Nasdaq: CDTX), Otonomy (Nasdaq: OTIC) and Collegium Pharmaceutical (Nasdaq: COLL). He is a former chair of BIOCOM, the Southern California life sciences trade association and in 2014, he was named the EY Entrepreneur of the Year for the San Diego region and was listed as a national finalist. He received a bachelor’s degree in management from Rutgers University.

What is Theodore R. Schroeder's net worth?: The estimated net worth of Theodore R. Schroeder is at least $0.00 as of August 27th, 2019. Mr. Schroeder owns 5,786 shares of Nabriva Therapeutics stock worth more than $0 as of December 22nd. This net worth approximation does not reflect any other investments that Mr. Schroeder may own. Learn More about Theodore R. Schroeder's net worth.
How do I contact Theodore R. Schroeder?: The corporate mailing address for Mr. Schroeder and other Nabriva Therapeutics executives is 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406. Nabriva Therapeutics can also be reached via phone at (531) 649-2000 and via email at [email protected]. Learn More on Theodore R. Schroeder's contact information.
Has Theodore R. Schroeder been buying or selling shares of Nabriva Therapeutics?: Theodore R. Schroeder has not been actively trading shares of Nabriva Therapeutics in the last ninety days. Learn More on Theodore R. Schroeder's trading history.
Who are Nabriva Therapeutics' active insiders?: Nabriva Therapeutics' insider roster includes J. Christopher Naftzger (General Counsel), Theodore Schroeder (CEO), and Stephen Webster (Director). Learn More on Nabriva Therapeutics' active insiders.

Theodore R. Schroeder Insider Trading History at Nabriva Therapeutics

Theodore R. Schroeder Buying and Selling Activity at Nabriva Therapeutics

Nabriva Therapeutics Company Overview

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Today's Range

Now: N/A

50 Day Range

MA: $0.03

$0.00

$1.42

2 Week Range

Now: N/A

Volume

40 shs

Average Volume

29,344 shs

Market Capitalization

$45.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53

I was wrong. Dead wrong.

From Porter & Company | Ad

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.